Brief: First Participant Dosed In Europe As Cognition Therapeutics Expand Phase 2 Alzheimer's Disease Trial Of Oral CT1812
15/12/2022 14:35
Dec 15 (Reuters) - Cognition Therapeutics Inc CGTX.O :
* FIRST PARTICIPANT DOSED IN EUROPE AS COGNITION
THERAPEUTICS
EXPAND PHASE 2 ALZHEIMER'S DISEASE CLINICAL TRIAL OF ORAL CT1812
Source text for Eikon: ID:nGNX27bTgV
Further company coverage: CGTX.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cognition Therapeutics
See all newsU.S. STOCKS ON THE MOVE-Quest Diagnostics, Tractor Supply, Dutch Bros
U.S. STOCKS ON THE MOVE-CME, Lockheed Martin, Valero Energy
Cognition rises after FDA backs late-stage trial plan for dementia drug
Brief: Cognition Therapeutics Announces Issuance Of Composition Of Matter Patent, Extending Protection For Zervimesine (CT1812) Through 2045
Brief: Cognition Therapeutics Schedules A Type C Meeting With FDA To Align On Endpoints For Phase 3 Trial Of Zervimesine (Ct1812) In DLB